Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Zepatier (elbasvir and grazoprevir by Year
Zepatier (elbasvir and grazoprevir — HCV, legacy) — International reported growth YoY (%) (%)
Merck Zepatier (elbasvir and grazoprevir: -44.0% in FY2019, up 6.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2019 figure comes from
“|| Zepatier | 370 | 455 | -19 | 118 | 8 | * | 252 | 447 | -44”
Source: Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zepatier (elbasvir and grazoprevir — HCV, legacy) — International reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | -44.0% | +6.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | -50.0% | – | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
Cite this data
StockData. (2026). Merck Zepatier (elbasvir and grazoprevir (%), annual FY2018–FY2019 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zepatier-intl-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.
See a number that looks wrong?